Clinical trials: Head and Neck Squamous Cell Carcinomas
Head and Neck Cancer
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
- Trial name
- NCT05608876
- Testing
- Tigilanol Tiglate
- Where
- 7 sites in Australia, United Kingdom
- Volunteers
- 15 people
- Sponsor
- QBiotics Group Limited
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
New Modalities for Detection of Oropharyngeal Cancer
Background: The incidence of human papilloma virus-driven oropharyngeal cancer (HPV-OPC), a type of head and neck cancer, is rapidly increasing within the US. Currently, there are no screening methods for early detection.
- Conditions
- Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, Base of Tongue Carcinoma, Tonsil Cancer
- Trial name
- NCT03226613
- Testing
- Transcervical Oropharyngeal Ultrasound, Oral Rinse Collection, Blood Draw
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Vanderbilt University Medical Center
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel.
- Trial name
- NCT01285635
- Testing
- AT-101, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Neoplasms
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Trial name
- ALPHA (NCT03695510)
- Testing
- Afatinib Oral Tablet, Pembrolizumab Injection
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer, Head and Neck Neoplasms
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04634825
- Testing
- Enoblituzumab, Retifanlimab, Tebotelimab
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 62 people
- Sponsor
- MacroGenics
Head and Neck Neoplasms
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
This prospective randomized controlled clinical Trial will be performed in patients with locally advanced squamous cell carcinoma of the head and neck.
- Trial name
- NCT03678649
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhejiang Cancer Hospital
Esophagus Cancer
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer. However, as high as more than 40% of patients with esophageal cancer experienced locoregional recurrence…
- Trial name
- EC-CRT-006 (NCT06143748)
- Testing
- Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Selenium
Sodium Selenite Supplementation in Patients With Head and Neck Cancer
The micronutrient selenium is an essential trace element in the human body. There are more than 25 proteins in the human body contain selenium, such as glutathione peroxidase and selenoprotein, which regulate the body's…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Selenium, Sodium Selenite
- Trial name
- NCT05451576
- Testing
- Zelnite®
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Mucosal Irritation, Image Quality
Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining
This study was to test an optimal concentration of Lugol's solution which can reduce the mucosal irritation and provide high image quality to ensure endoscopy examination by a randomized blinded controlled trial.
- Trial name
- NCT03180944
- Testing
- 1.2% Lugol's solution, 1.0% Lugol's solution, 0.8% Lugol's solution
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shandong University
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed…
- Trial name
- eVOLVE-HNSCC (NCT06129864)
- Testing
- volrustomig
- Where
- 306 sites in United States, Austria and 21 more
- Volunteers
- 1,145 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of Head and Neck
Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall)
The investigators test the effect of providing individualized prognostic information on life-expectancy to head and neck cancer patients in the palliative phase.
- Trial name
- ProCoPall (NCT06699316)
- Testing
- Individualized prognostic counselling
- Where
- Netherlands
- Volunteers
- 160 people
- Sponsor
- Erasmus Medical Center
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
- Trial name
- NCT05952947
- Testing
- HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HRYZ Biotech Co.
Head and Neck Squamous Cell Cancer
Head and Neck Cancer Screening and Serum Repository
Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol.
- Trial name
- NCT00592371
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Carcinoma, Squamous Cell of Head and Neck
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
The trial is designed as a multi-center, open label Phase 2 trial that investigates the efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT01417936
- Testing
- Sym004
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 26 people
- Sponsor
- Symphogen A/S
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition.
- Trial name
- NIVOTAX (NCT04282109)
- Testing
- Nivolumab + Paclitaxel, Cetuximab + Paclitaxel
- Where
- 21 sites in Spain
- Volunteers
- 141 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal…
- Trial name
- NEOCRTEC2501 (NCT07638436)
- Testing
- Adebrelimab Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
This pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01473784
- Testing
- transoral robotic surgery, quality of life assessment
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives: To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00268671
- Testing
- Docetaxel
- Volunteers
- 45 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.